THE COST-EFFECTIVENESS OF CANAGLIFLOZIN COMPARED WITH LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED WITH METFORMIN AND SULFONYLUREA IN FRANCE

被引：1
|
作者：
Troelsgaard, A. [1 ]
Pitcher, A. [2 ]
Granados, D. [3 ]
Hemels, M. [1 ]
Lloyd, A. [2 ]
机构：
[1] Janssen AS, Birkerod, Denmark
[2] IMS Hlth, London, England
[3] Janssen, Paris, France
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.707
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB85
引用
收藏
页码：A346 / A347
页数：2
相关论文
共 50 条
  • [21] Liraglutide in Combination with Metformin or Sulfonylurea for the Treatment of Type 2 Diabetes in Adult Patients
    Udiawar, Maneesh V.
    Bain, Stephen C.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2012, 4 : 251 - 261
  • [22] COST-EFFECTIVENESS OF CANAGLIFLOZIN (CANA) VERSUS SITAGLIPTIN (SITA) AS ADD-ON TO METFORMIN PLUS SULFONYLUREA IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN BRAZIL
    Pititto, L.
    Neslusan, C.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    Asano, E.
    Puig, A.
    VALUE IN HEALTH, 2015, 18 (07) : A864 - A864
  • [23] Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy
    Lukashevich, V.
    Wang, M.
    Del Prato, S.
    Araga, M.
    Kothny, W.
    DIABETOLOGIA, 2012, 55 : S353 - S353
  • [24] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Gordon, Jason
    McEwan, Phil
    Hurst, Michael
    Puelles, Jorge
    DIABETES THERAPY, 2016, 7 (04) : 825 - 845
  • [25] COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
    Ramirz de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    VALUE IN HEALTH, 2014, 17 (03) : A249 - A250
  • [26] COST-EFFECTIVENESS OF SITAGLIPTIN VERSUS SULFONYLUREA AS AN AD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN A BELGIUM SETTING
    Chen, J.
    Radican, L.
    Shankar, R.
    Hiver, M.
    Qiu, Y.
    VALUE IN HEALTH, 2014, 17 (07) : A349 - A349
  • [27] The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Jason Gordon
    Phil McEwan
    Michael Hurst
    Jorge Puelles
    Diabetes Therapy, 2016, 7 : 825 - 845
  • [28] The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus
    Charokopou, M.
    McEwan, P.
    Lister, S.
    Callan, L.
    Bergenheim, K.
    Tolley, K.
    Postema, R.
    Townsend, R.
    Roudaut, M.
    DIABETIC MEDICINE, 2015, 32 (07) : 890 - 898
  • [29] COST-EFFECTIVENESS OF CANAGLIFLOZIN TREATMENT IN CHINESE PATIENTS WITH TYPE 2 DIABETES AND KIDNEY DISEASE
    Wu, B.
    VALUE IN HEALTH, 2019, 22 : S584 - S584
  • [30] COST EFFECTIVENESS EVALUATION OF CANAGLIFLOZIN IN COMBINATION WITH METFORMIN AND SULFONYLUREA IN COMPARISON TO NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN POLAND
    Szmurlo, D.
    Drzal, R.
    Plisko, R.
    Schubert, A.
    Skrzekowska-Baran, I
    VALUE IN HEALTH, 2014, 17 (07) : A351 - A351
12345